Phosphorylation |
RhoA |
PKA |
S188 |
Increasing interaction with RhoGDI |
[21,22] |
Decreases binding to ROCK effector |
Protection of RhoA from degradation |
PKG |
S188 |
Translocation to the cytosol |
[23] |
Protection of RhoA from degradation |
PKC |
T127 and S188 |
Translocation to the plasma membrane |
[24] |
Protection of RhoA from degradation |
c-Met |
Tyr42 |
Proteasomal degradation |
[25] |
Rac1 |
ERK |
T108 |
RAC1 for translocation to the nucleus |
[26] |
FAK |
Y64 |
Inhibit RAC1 activity |
[27] |
SRC |
Y64 |
Inhibit RAC1 activity |
[27] |
AKT |
S71 |
Inhibits RAC1 activity |
[28] |
Cdc42 |
SRC |
Y64 |
Increasing interaction with RhoGDI |
[29] |
PKA |
S185 |
Increasing interaction with RhoGDI |
[30] |
Ubiquitination |
RhoA |
SMURF1 |
K6,K7 and K51 |
Proteasomal degradation |
[31] |
SCF |
K135 |
Proteasomal degradation in a ERK-dependent manner |
[32] |
CUL3 |
ND |
Proteasomal degradation of GDP-bound inactive RhoA |
[33] |
Rac1 |
XIAP and clAP1 |
K147 |
Proteasomal degradation |
[34] |
HACE1 |
K147 |
Targets GTP-bound, active RAC1 for degradation |
[35] |
SCF |
K166 |
Proteasomal degradation in a AKT-dependent manner |
[36] |
Transglutamination |
RhoA |
CNF1 |
E63 |
Constitutive activation |
[37] |
Rac1 |
CNF1 |
E61 |
Constitutive activation |
[37] |
Cdc42 |
CNF1 |
E61 |
Constitutive activation |
[37] |
AMPylation |
RhoA |
HYPE |
T37 |
Suppress effector binding |
[38] |
Rac1 |
HYPE |
T35 |
Suppress effector binding |
[38] |
Cdc42 |
HYPE |
T35 |
Suppress effector binding |
[38] |
SUMOylation |
Rac1 |
PIAS3 |
K183,K184,K186 and K188 |
Increased GTP binding and RAC1 activation |
[39,40] |